UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Piroxicam

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A6	OAT1	Piroxicam	20.5		Adefovir	CHO-OAT1	Mulato, 2000
SLCO2B1	OATP2B1, OATP-B	Piroxicam	35.42		Dibromofluorescein	HEK293-OATP2B1	Unger, 2020
ABCC2	MRP2, cMOAT	Piroxicam	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC3	MRP3	Piroxicam	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC4	MRP4	Piroxicam	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
SLC22A11	OAT4	Piroxicam	84.9		Estrone sulfate	S2-OAT4	Khamdang, 2002
SLC22A8	OAT3	Piroxicam	2.52		Estrone sulfate	S2-OAT3	Khamdang, 2002
SLC22A6	OAT1	Piroxicam		19.8	Ochratoxin A	S2-OAT1	Jung, 2001
SLC22A8	OAT3	Piroxicam		4.88	Ochratoxin A	S2-OAT2	Jung, 2001
SLC22A11	OAT4	Piroxicam		107.8	Ochratoxin A	S2-OAT4	Babu, 2002
SLC22A6	OAT1	Piroxicam	62.8		Para-aminohippurate	S2-OAT1	Khamdang, 2002
SLC22A7	OAT2	Piroxicam	70.3		Prostaglandin F2-alpha	S2-OAT2	Khamdang, 2002
ABCB11	BSEP	Piroxicam	>133		Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.